久久亚洲国产成人影院-久久亚洲国产的中文-久久亚洲国产高清-久久亚洲国产精品-亚洲图片偷拍自拍-亚洲图色视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Chinese biotech firm BeiGene's plans move into high gear

By Qiu Quanlin in Guangzhou | chinadaily.com.cn | Updated: 2020-12-17 10:34
Share
Share - WeChat
A technician carries out a test at a pharmaceutical company in Beijing. [Photo/Xinhua]

Construction of the third plant of BeiGene Ltd, a Chinese biotechnology company, along with the completion of its second plant in Guangzhou, the capital of Guangdong province, will help boost the company's production capacity and upgrade its manufacturing technique, according to a senior executive.

BeiGene announced construction of the third plant and completion of its second one in its biopharmaceutical manufacturing base in Guangzhou on Wednesday.

"The second and third plants will enable us to produce verified biopharmaceutical products, helping us reduce production cost and increase efficiency," said Michael Garvey, vice-president of BeiGene.

After the completion of its second plant, BeiGene's manufacturing base in Guangzhou has a production capacity of 24,000 liters of biopharmaceuticals, according to the company sources.

The base will become one of the largest domestic biopharmaceutical manufacturing hubs, as its production capacity is expected to increase to 64,000 liters, following the completion of its third plant.

"Advanced facilities, along with introduction of artificial intelligence and automation techniques, helped us to develop innovative biopharmaceutical products, which are already witnessing high demand both on the Chinese and global markets," said Garvey.

Founded in Beijing in 2010 as a biotechnology company, BeiGene completed construction of a small molecule manufacturing facility in Suzhou of Jiangsu province in 2016 and the initial phase of a bio-manufacturing base in Guangzhou in 2019.

The company's self-developed cancer drug, known as Brukinsa (zanubrutinib) in capsule form, was granted market access by the National Medical Products Administration in June this year.

The drug is for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy, and also for adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

In November last year, the independently-developed new cancer therapy also received approval from the US Food and Drug Administration as a treatment for MCL in adult patients who have received at least one prior therapy.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 久久精品国产亚洲7777 | 日韩中文字幕在线亚洲一区 | 日本无卡码免费一区二区三区 | 成人91在线| 日本 欧美 国产 | 高清国产精品久久久久 | 国产一级网站 | 成人免费视频在线 | 国产福利微拍精品一区二区 | 欧美日韩亚洲一区二区三区 | 福利国产视频 | 亚洲精品在线看 | 国产精品视频久久久久 | 久久国产精品亚洲 | 一级片免费观看视频 | 日韩偷拍自拍 | 18视频网站在线观看 | 国产高清在线 | 国产看午夜精品理论片 | 国产成人综合网亚洲欧美在线 | 午夜a一级毛片一.成 | 99在线国产视频 | 国产亚洲精品资源一区 | 免费国产午夜高清在线视频 | 美女拍拍拍爽爽爽爽爽爽 | 亚洲精品视频免费观看 | 欧美xx在线观看 | 香蕉视频黄色在线观看 | 成人毛片18女人毛片免费 | 特黄特黄aaaa级毛片免费看 | 欧美成在线 | 中文字幕在线观看亚洲日韩 | 国产成人免费网站在线观看 | 久久精品国产99国产精品 | 久久免费看视频 | 国产无套视频在线观看香蕉 | 美女又黄又免费 | 国产精品久久久久久免费 | 在线免费亚洲 | 成人a在线| 欧美成a人免费观看久久 |